Skip to Content
Top

BY Laura Sussman

In a pilot study conducted at MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy and/or targeted therapy, neoadjuvant systemic therapy (NST). Should the findings be replicated in future studies, this research would be the first indication that as the field moves toward more selective, personalized treatment, surgery may altogether...

breast cancer treatment triple negative breast cancer

BY Laura Sussman

In the first study evaluating patient-reported cosmetic outcomes in older women with breast cancer, MD Anderson researchers found that...

BY Ron Gilmore

The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall survival...

BY MD Anderson staff

In the modern world of biomedical research, collaborations between academic institutions and pharmaceutical and biotech companies have become more and more prevalent, necessary and efficient.

Created in 2013, MD Anderson’s Strategic Industry Ventures attracts, maintains and grows such collaborations that will help advance new biomedical discoveries

Totaling close to 40 alliances and partnerships so far, MD Anderson...

Strategic Industry Ventures Institute for Applied Cancer Sciences

BY Clayton Boldt, Ph.D.

Certain quality-of-life factors, such as pain and anxiety, have a significant impact on the likelihood of endometrial cancer survivors to...

BY Ron Gilmore

A study by MD Anderson researchers is shedding new light on how the protein PD-L1 suppresses the immune system, which may help scientists...